Expression of clinically relevant drug-metabolizing enzymes along the human intestine and their correlation to drug transporters and nuclear receptors: An intra-subject analysis
- PMID: 30253071
- DOI: 10.1111/bcpt.13137
Expression of clinically relevant drug-metabolizing enzymes along the human intestine and their correlation to drug transporters and nuclear receptors: An intra-subject analysis
Abstract
The oral bioavailability of many drugs is highly influenced not only by hepatic but also by intestinal biotransformation. To estimate the impact of intestinal phase I and II metabolism on oral drug absorption, knowledge on the expression levels of the respective enzymes is an essential prerequisite. In addition, the potential interplay of metabolism and transport contributes to drug disposition. Both mechanisms may be subjected to coordinative regulation by nuclear receptors, leading to unwanted drug-drug interactions due to induction of intestinal metabolism and transport. Thus, it was the aim of this study to comprehensively analyse the regional expression of clinically relevant phase I and II enzymes along the entire human intestine and to correlate these data to expression data of drug transporters and nuclear receptors of pharmacokinetic relevance. Gene expression of 11 drug-metabolizing enzymes (CYP2B6, 2C8, 2C9, 2C19, 2D6, 3A4, 3A5, SULT1A, UGT1A, UGT2B7, UGT2B15) was studied in duodenum, jejunum, ileum and colon from six organ donors by real-time RT-PCR. Enzyme expression was correlated with expression data of the nuclear receptors PXR, CAR and FXR as well as drug transporters observed in the same cohort. Intestinal expression of all studied metabolizing enzymes was significantly higher in the small intestine compared to colonic tissue. CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5, SULT1A, UGT1A and UGT2B7 expression increased from the duodenum to jejunum but was markedly lower in the ileum. In the small intestine, that is, the predominant site of drug absorption, the highest expression has been observed for CYP3A4, CYP2C9, SULT1A and UGT1A. In addition, significant correlations were found between several enzymes and PXR as well as ABC transporters in the small intestine. In conclusion, the observed substantial site-dependent intestinal expression of several enzymes may explain regional differences in intestinal drug absorption. The detected correlations between intestinal enzymes, transporters and nuclear receptors provide indirect evidence for their coordinative expression, regulation and function in the human small intestine.
Keywords: gene expression; intestine; metabolizing enzymes; nuclear receptors; transporters.
© 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
Similar articles
-
Protein Abundance of Clinically Relevant Drug-Metabolizing Enzymes in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens.Clin Pharmacol Ther. 2018 Sep;104(3):515-524. doi: 10.1002/cpt.967. Epub 2017 Dec 29. Clin Pharmacol Ther. 2018. PMID: 29205295
-
Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs.J Clin Pharmacol. 2007 May;47(5):566-78. doi: 10.1177/0091270007299930. J Clin Pharmacol. 2007. PMID: 17442683 Review.
-
Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine.Drug Metab Dispos. 2020 Apr;48(4):245-254. doi: 10.1124/dmd.119.089656. Epub 2020 Jan 20. Drug Metab Dispos. 2020. PMID: 31959703 Free PMC article.
-
Dysregulation of Mucosal Membrane Transporters and Drug-Metabolizing Enzymes in Ulcerative Colitis.J Pharm Sci. 2019 Feb;108(2):1035-1046. doi: 10.1016/j.xphs.2018.09.024. Epub 2018 Sep 26. J Pharm Sci. 2019. PMID: 30267783
-
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.Pharm Res. 2006 Aug;23(8):1675-86. doi: 10.1007/s11095-006-9041-2. Pharm Res. 2006. PMID: 16841194 Review.
Cited by
-
Activity and mRNA expression levels of selected cytochromes P450 in various sections of the human small intestine.Br J Clin Pharmacol. 2019 Jun;85(6):1367-1377. doi: 10.1111/bcp.13908. Epub 2019 Apr 13. Br J Clin Pharmacol. 2019. PMID: 30817016 Free PMC article.
-
An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials.Drug Metab Dispos. 2019 Jun;47(6):601-615. doi: 10.1124/dmd.119.086397. Epub 2019 Mar 25. Drug Metab Dispos. 2019. PMID: 30910785 Free PMC article.
-
Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap.Front Pharmacol. 2022 Oct 7;13:962718. doi: 10.3389/fphar.2022.962718. eCollection 2022. Front Pharmacol. 2022. PMID: 36278150 Free PMC article. Review.
-
Transporters in the Mammary Gland-Contribution to Presence of Nutrients and Drugs into Milk.Nutrients. 2019 Oct 5;11(10):2372. doi: 10.3390/nu11102372. Nutrients. 2019. PMID: 31590349 Free PMC article. Review.
-
Analysis of 1,25-dihydroxyvitamin D genomic action in human enteroids and colonoids reveals multiple regulatory effects of vitamin D in human intestinal physiology.Front Endocrinol (Lausanne). 2025 Jun 4;16:1538463. doi: 10.3389/fendo.2025.1538463. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40535337 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources